An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)
Pluvicto 1 000 MBq/mL solution for injection/infusionLocametz 25 micrograms kit for radiopharmaceutical preparation
Eligibility
Age group
65+ years, 18-64 years
Sex
Female
Primary endpoint
Incidence of DLTs during the DLT observation period (DLT and DLT observation period as defined in protocol section 2.4.1), Co-primary safety endpoint: Frequency and nature of treatment-emergent adverse events (TEAEs).
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.